Ip­ca Lab­o­ra­to­ries cit­ed for qual­i­ty is­sues at In­dia fa­cil­i­ty that pro­duces API

The FDA iden­ti­fied sev­er­al qual­i­ty is­sues at a plant in In­dia owned by Ip­ca Lab­o­ra­to­ries that makes ac­tive phar­ma­ceu­ti­cal in­gre­di­ents.

In the sev­en-page in­spec­tion re­port, the FDA cit­ed sev­er­al is­sues dur­ing an in­spec­tion at a fa­cil­i­ty in Pi­paria, In­dia, that took place be­tween April 18 to 26.

The in­spec­tion found that the site had not prop­er­ly in­ves­ti­gat­ed sev­er­al batch­es of prod­ucts, shared re­sults with­out get­ting to the root of is­sues in some cas­es, and had not prop­er­ly fol­lowed the in­ves­ti­ga­tion­al pro­ce­dure in oth­er cas­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER